SHERRIE HARRELL: Open Payments
NPI 1811230691 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,678 in 78 payments from 17 companies in 2025. Trend: 2023 $1,711 · 2024 $1,609 · 2025 $1,678
Food & beverage: $1,601Education: $77
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 9 | $225 |
| ABBVIE INC. | 15 | $222 |
| Ipsen Biopharmaceuticals, Inc | 6 | $214 |
| Regeneron Healthcare Solutions, Inc. | 6 | $159 |
| Aimmune Therapeutics, Inc. | 8 | $149 |
| Lilly USA, LLC | 9 | $147 |
| Janssen Biotech, Inc. | 4 | $135 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $63 |
| Braintree Laboratories, Inc. | 4 | $58 |
Products named: IQIRVO, TREMFYA, DUPIXENT, ZENPEP, OMVOH, XIFAXAN, RINVOQ, LINZESS.
Industry payments across AR — which companies pay providers there.
